A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date8/28/17 → 8/27/19

Funding

  • Bristol-Myers Squibb Company ( Award # ): $10,480.77